Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa

Opiant Pharmaceuticals (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has completed patient enrollment in its Phase 2 clinical trial of OPTN001, a naloxone nasal spray, for the treatment of Bulimia Nervosa. The Company expects to report top-line data from this trial in the first quarter of 2019.

As quoted in the press release:

Bulimia Nervosa is a serious eating disorder characterized by binging and purging that impacts about one million Americans.  Treatment of Bulimia Nervosa can be challenging, with as many as 30 percent of patients relapsing.  Fluoxetine, an orally administered antidepressant, is the only drug currently approved for this indication; however, it has shown limited efficacy.

“OPNT001 has the potential to address the unique needs of this patient population because it has demonstrated a rapid absorption profile and allows for on-demand dosing by patients when they experience the urge to binge,” said Susan McElroy, M.D., an eating disorders expert at the Lindner Center of HOPE.  “This can help to establish a sense of control, which patients with Bulimia desperately want, and if bingeing is controlled, patients won’t carry out compensatory behaviors, primarily purging.  It may also support medication adherence because once OPNT001 is administered intranasally, the treatment cannot be purged.”

Click here to read the full press release.